| The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study SK Mahil, K Bechman, A Raharja, C Domingo-Vila, D Baudry, MA Brown, ... The Lancet Rheumatology 3 (9), e627-e637, 2021 | 165 | 2021 |
| Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern L Dupont, LB Snell, C Graham, J Seow, B Merrick, T Lechmere, ... Nature microbiology 6 (11), 1433-1442, 2021 | 99 | 2021 |
| Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study SK Mahil, K Bechman, A Raharja, C Domingo-Vila, D Baudry, MA Brown, ... The Lancet Rheumatology 4 (1), e42-e52, 2022 | 76 | 2022 |
| Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in … P Harrington, KJ Doores, D Radia, A O’Reilly, HPJ Lam, J Seow, ... British journal of haematology 194 (6), 999-1006, 2021 | 62 | 2021 |
| Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative … P Harrington, H de Lavallade, KJ Doores, A O’Reilly, J Seow, C Graham, ... Leukemia 35 (12), 3573-3577, 2021 | 46 | 2021 |
| Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients P Harrington, KJ Doores, C Saha, J Saunders, F Child, R Dillon, ... Cancer cell 39 (11), 1448-1449, 2021 | 38 | 2021 |
| Broad neutralization of SARS-CoV-2 variants, including omicron, following breakthrough infection with Delta in COVID-19-vaccinated individuals T Lechmere, LB Snell, C Graham, J Seow, ZA Shalim, T Charalampous, ... Mbio 13 (2), e03798-21, 2022 | 35 | 2022 |
| Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer DR McKenzie, M Muñoz-Ruiz, L Monin, T Alaguthurai, T Lechmere, ... Cancer Cell 39 (11), 1445-1447, 2021 | 31 | 2021 |
| ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants J Seow, C Graham, SR Hallett, T Lechmere, TJA Maguire, I Huettner, ... Cell Reports 39 (5), 2022 | 12 | 2022 |
| Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B. 1.1. 7 infections L Dupont, LB Snell, C Graham, J Seow, B Merrick, T Lechmere, SR Hallett, ... MedRxiv, 2021 | 11 | 2021 |
| The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern C Graham, T Lechmere, A Rehman, J Seow, A Kurshan, I Huettner, ... PLoS Pathogens 18 (10), e1010882, 2022 | 8 | 2022 |
| Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib P Harrington, KJ Doores, J Saunders, M de Lord, C Saha, T Lechmere, ... Blood cancer journal 12 (4), 73, 2022 | 8 | 2022 |
| Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nat Microbiol 6: 1433–1442 L Dupont, LB Snell, C Graham, J Seow, B Merrick, T Lechmere, ... | 7 | 2021 |
| BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes S Abdul-Jawad, R Beatson, T Lechmere, R Graham, T Alaguthurai, ... haematologica 107 (5), 1181, 2022 | 6 | 2022 |
| Omicron breakthrough infections in vaccinated or previously infected hamsters J Zhou, K Sukhova, TP Peacock, PF McKay, JC Brown, R Frise, L Baillon, ... Proceedings of the National Academy of Sciences 120 (45), e2308655120, 2023 | 4 | 2023 |
| Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA. 1 breakthrough infection J Seow, ZA Shalim, C Graham, S Kimuda, A Pillai, T Lechmere, ... Mbio 14 (5), e01206-23, 2023 | 2 | 2023 |
| Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer DR McKenzie, R Graham, T Lechmere, C Domingo-Vila, T Alaguthurai, ... Cancer research communications 2 (11), 1449-1461, 2022 | 2 | 2022 |
| Low frequency of T cell and antibody responses to vaccination against sars-Cov-2 in patients post allogeneic stem cell transplantation in comparison with chronic myeloid … P Harrington, K Doores, C Saha, J Saunders, DH Radia, S Kordasti, ... Blood 138, 3920, 2021 | 1 | 2021 |
| Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML P Harrington, KJ Doores, D Radia, A O’Reilly, HP Jeff Lam, J Seow, ... medRxiv, 2021.04. 15.21255482, 2021 | 1 | 2021 |
| Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study SK Mahil, K Bechman, A Raharja, D Baudry, M Brown, A Cope, T Dasandi, ... Arthritis & Rheumatology, 4126-4130, 2021 | 1 | 2021 |
